Drug Trial Radar · NCT06275620
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
Last checked: Nov 20, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
24
Planned (sponsor's estimate)
Start
Nov 14, 2023
Primary completion
Nov 2025
Study completion Dec 2029
Sponsor
- Lead sponsor
- Beacon TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.
Conditions
- X-Linked Retinitis Pigmentosa
Interventions
AGTC-501 (high dose and standard corticosteroid regimen)Biological
Adeno-associated virus vector expressing a human RPGR gene
AGTC-501 (low dose and standard corticosteroid regimen)Biological
Adeno-associated virus vector expressing a human RPGR gene
AGTC-501 (high dose and modified corticosteroid regimen)Biological
Adeno-associated virus vector expressing a human RPGR gene
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary safety outcome is the number of participants experiencing Grade 3 or higher local (ocular) or non-ocular treatment-emergent adverse events, including treatment-emergent serious adverse events (SAEs).Time frame: Day 0 - Month 12
- The primary safety outcome is the proportion of participants experiencing Grade 3 or higher local (ocular) or non-ocular treatment-emergent adverse events, including treatment-emergent serious adverse events (SAEs).Time frame: Day 0 - Month 12
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Florida
Jacksonville, Florida
Bascom Palmer Eye Institute
Miami, Florida
Boston Children's Hospital
Boston, Massachusetts
Cincinnati Eye Institute
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Casey Eye Institute
Portland, Oregon
Retina Foundation of the Southwest
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.